ASH 2020

Asciminib may be a new treatment option for patients with chronic myeloid leukemia in the chronic phase (CML-CP).

Hypogammaglobulinemia often occurs in patients with chronic lymphocytic leukemia who receive CAR-T, but there is no standard way to manage it.

A novel assay was shown to precisely quantify CAR T cells in circulation and distinguish responders from nonresponders.

Responses lasted for a median of 21.8 months, and patients had a median PFS of 18.8 months.

Idecabtagene vicleucel showed clinical benefit and no toxicity concerns in patients with relapsed and/or refractory multiple myeloma.

A CAR-T therapy that targets B-cell maturation antigen showed clinical activity in heavily pretreated patients with relapsed/refractory multiple myeloma.

Investigators performed post hoc subgroup analyses by age in patients with relapsed/refractory indolent lymphoma from the MAGNIFY study.

Dr Samur and colleagues found that high-dose melphalan caused an approximately 2.5-fold greater mutation accumulation rate than that observed with RVD treatment alone.

Patients with AML or MDS were significantly more likely to die from COVID-19 vs other HMs. Most treatments did not improve survival outcomes — except corticosteroids.

The limited data underscore “a potential role for passive immunity in this disease,” according to the presenting researcher.